Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCFTTN)

Drug Name
Runcaciguat Drug Info
Synonyms
Runcaciguat; 1402936-61-1; Runcaciguat [INN]; 5EZ01YDT5S; UNII-5EZ01YDT5S; (3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; CHEMBL4650322; SCHEMBL20075857; GTPL12359; AKOS040742586; BAY1101042; BAY 1101042; BAY-1101042; compound 45 [PMID: 33872507]; AC-37098; MS-29070; HY-109136; CS-0086784; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; XZ7
Indication
Disease Entry ICD 11 Status REF
Chronic kidney disease GB61 Phase 2 [1]
Non-proliferative diabetic retinopathy 9B71.00 Phase 2 [2]
Cross-matching ID
PubChem CID
134440946
TTD Drug ID
DMCFTTN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Soluble guanylate cyclase (GCS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [4]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [5]
Sodium nitroprusside DMGA9X0 Hypertension BA00-BA04 Approved [6]
IW-1973 DMK2T7J Heart failure BD10-BD13 Phase 2 [7]
CTI-1601 DMM4JMB Friedreich's ataxia 8A03.10 Phase 2 [8]
MK-5475 DMIIZ4R Pulmonary arterial hypertension BB01.0 Phase 2 [9]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [10]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [11]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Activator [3]

References

1 ClinicalTrials.gov (NCT04507061) A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Individually Titrated Oral Doses of Runcaciguat in Subjects With Clinical Diagnosis of Chronic Kidney Disease With Diabetes and/or Hypertension and at Least One Cardiovascular Comorbidity. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04722991) A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy. U.S.National Institutes of Health.
3 Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
4 Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
5 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
6 Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
9 Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.
10 First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
11 Clinical pipeline report, company report or official report of Cyclerion Therapeutics